Peter Fernandes
Président chez The Pulmonary Vascular Research Institute
Fortune : 2 079 $ au 31/05/2024
Profil
Peter Fernandes is currently the Co-Chairman at The Pulmonary Vascular Research Institute.
He previously worked as the Vice President-Global Regulatory Affairs at Ikaria, Inc. from 2012 to 2015, Head-Regulatory Affairs & Quality Assurance at OptiNose, Inc. from 2010 to 2012, VP-Regulatory Affairs & Quality Assurance at ALTANA Pharma US, Inc. from 2005 to 2007, and Vice President-US Drug Regulatory Affairs at Novartis Pharmaceuticals AG from 2007 to 2010.
He is also currently the Chief Executive, Financial & Accounting Officer at Bellerophon Therapeutics, Inc. starting from 2015.
Mr. Fernandes received his graduate degree from The Grant Government Medical College in 1982 and his undergraduate degree from Principal K.
M.
Kundnani College of Pharmacy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/10/2023 | 34 649 ( 0,28% ) | 2 079 $ | 31/05/2024 |
Postes actifs de Peter Fernandes
| Sociétés | Poste | Début |
|---|---|---|
The Pulmonary Vascular Research Institute
 The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Président | - |
Anciens postes connus de Peter Fernandes
| Sociétés | Poste | Fin |
|---|---|---|
| BELLEROPHON THERAPEUTICS, INC. | Directeur Général | 15/11/2023 |
| IKARIA, INC. | Conseiller Juridique Général | 01/05/2015 |
| OPTINOSE, INC. | Conseiller Juridique Général | 01/09/2012 |
| Novartis Pharmaceuticals AG | Corporate Officer/Principal | 01/10/2010 |
ALTANA Pharma US, Inc.
 ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | Conseiller Juridique Général | 01/10/2007 |
Formation de Peter Fernandes
| The Grant Government Medical College | Graduate Degree |
| Principal K. M. Kundnani College of Pharmacy | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OPTINOSE, INC. | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
ALTANA Pharma US, Inc.
ALTANA Pharma US, Inc. Pharmaceuticals: MajorHealth Technology ALTANA Pharma US, Inc. develops respiratory and gastrointestinal products. The company is headquartered in Florham Park, NJ. | Health Technology |
The Pulmonary Vascular Research Institute
The Pulmonary Vascular Research Institute Miscellaneous Commercial ServicesCommercial Services The Pulmonary Vascular Research Institute operates as a medical research charity. The non-profit company is based in Canterbury, UK. | Commercial Services |
| Novartis Pharmaceuticals AG |
